- Education
- Source: Campus Sanofi
- 23 Oct 2023
The Continuing Role of Secondary Care in Lipid Optimisation Post-ACS
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/header-5.jpg3/jcr:content/header-5.jpg)
Prescribing information is available by clicking the links at the bottom of the page
The Continuing Role of Secondary Care in Lipid Optimisation Post-ACS
Length: 6:59
Dr Rani Khatib discusses the reasons why post-MI secondary prevention clinics should be established, explains the Leeds cardiometabolic medicines optimisation pathway and their multidisciplinary innovative medicines clinic for PCSK9i & statin intolerance, the benefits to patients and healthcare system, and the challenges to overcome.
Videos From the Same Series
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/MicrosoftTeams-image--17---18-.png/jcr:content/MicrosoftTeams-image%20(17)%20(18).png)
Implementing Artifical Intelligence to Risk Stratify, Manage and Refer Patients | Praluent® (alirocumab)
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/MicrosoftTeams-image--17---19-.png/jcr:content/MicrosoftTeams-image%20(17)%20(19).png)
What's the Future of Secondary Care Lipid Services | Praluent® (alirocumab)
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/MicrosoftTeams-image--17---20-.png/jcr:content/MicrosoftTeams-image%20(17)%20(20).png)
Strengthening the Interface between Primary and Secondary Care | Praluent® (alirocumab)
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/MicrosoftTeams-image--17---18-.png/jcr:content/MicrosoftTeams-image%20(17)%20(18).png)
Implementing Artifical Intelligence to Risk Stratify, Manage and Refer Patients | Praluent® (alirocumab)
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/MicrosoftTeams-image--17---19-.png/jcr:content/MicrosoftTeams-image%20(17)%20(19).png)
What's the Future of Secondary Care Lipid Services | Praluent® (alirocumab)
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/MicrosoftTeams-image--17---20-.png/jcr:content/MicrosoftTeams-image%20(17)%20(20).png)
Strengthening the Interface between Primary and Secondary Care | Praluent® (alirocumab)
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Patient-Supports/MicrosoftTeams-image--2-.png0/jcr:content/MicrosoftTeams-image%20(2).png)
MAT-XU-2300475 (v4.0) Date of Preparation: March 2024